Experience and efficacy of SBRT for lung cancer: an analysis of 142 patients
10.3760/cma.j.cn113030-20190325-00107
- VernacularTitle:142例早期非小细胞肺癌SBRT长期预后观察
- Author:
Baiqiang DONG
1
;
Jin WANG
;
Yujin XU
;
Xiao HU
;
Xianghui DU
;
Guoping SHAN
;
Kainan SHAO
;
Xue BAI
;
Ming CHEN
Author Information
1. 中国科学院大学附属肿瘤医院(浙江省肿瘤医院)放疗科，中国科学院肿瘤与基础医学研究所，杭州 310022
- From:
Chinese Journal of Radiation Oncology
2020;29(6):416-420
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the clinical efficacy and safety of stereotactic body radiation therapy (SBRT) for stage Ⅰ-Ⅱ non-small cell lung cancer.Methods:Retrospective analysis of patients with early stage lung cancer who received SBRT in Zhejiang Cancer Hospital from 2012 to 2018 was conducted. The Kaplan-Meier method was used for survival analysis. The main endpoints of the study were locoregional control (LRC) and cancer specific survival (CSS).Results:A total of 142 eligible cases were included, with a median BED10100Gy (100-132Gy). The median age was 75.6 years (47.2-89.0 years), among which 75 patients were aged (greater than or equal to 75 years old). The median follow-up time was 31.0 months, for patients< 75 years old and patients ≥ 75 years old. The 5-year LRC were 84.5% and 95.8% respectively, 5-year CSS were 72.4% and 78.6% respectively, for patients< 75 years old and elderly patients. The systemic response was mild during treatment, no grade 4-5 adverse events occurred in all patients. The main acute side effect was radiation pneumonitis (RP) below grade 3. Grade 2 RP appeared in 14 patients (9.9%) after SBRT where grade 3 RP occurred in 2(1.4%). There was no treatment-related mortality in the SBRT group.Conclusions:SBRT is a safe and effective treatment for early primary lung cancer with satisfactory rates of LRC and CSS in 5 years and mild complication, which is similar to previous reports.
